ACA vs FCN

The company exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. Despite strong recent earnings growth (YoY EPS +71.4%, Earnings Growth YoY +335.3%) and solid revenue momentum (24.60% YoY), elevated valuation metrics (P/E 38.61 vs. sector avg 55.59) and bearish insider activity weigh on near-term outlook. The stock trades significantly above the Graham Number of $59.01, suggesting overvaluation for defensive investors, though growth investors may justify the premium. Analysts maintain a strong_buy consensus, but insider selling and modest dividend strength temper enthusiasm.

FCN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a conservative Debt/Equity ratio of 0.36. While the current price of $184.23 is significantly above the defensive Graham Number ($103.01), it remains well below the growth-based intrinsic value of $243.08. The company demonstrates exceptional earnings quality with a PEG ratio of 0.96 and a consistent track record of beating analyst estimates. Despite bearish technical trends and minor insider selling, the underlying financial trajectory is robust.